Mi­rati’s drug sitra­va­tinib flops PhI­II in com­bo with Op­di­vo for cer­tain lung can­cer

Mi­rati Ther­a­peu­tics’ path to a sec­ond drug ap­proval will like­ly have to wait. The San Diego biotech com­pa­ny said Wednes­day that its in­ves­ti­ga­tion­al lung can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER